Our group focuses on developing targeted therapies for rare immunological conditions, such as primary immunodeficiency diseases and immunological conditions of unknown origin.
We aim to optimize the CRISPR-Cas gene editing technology as a gene therapy in these diseases, and stratify the existing therapies – such as biologic drugs and small molecule inhibitors – to better target the underlying molecular pathways that malfunction in individual patients.
We utilise custom genomics and high-throughput screening to understand immune diseases and optimize CRISPR-Cas9 genome editing towards safe and efficient use in patients. We work with cell models and patient material.
Our international team is based at the Norwegian Centre for Molecular Biosciences and Medicine (NCMBM) in Oslo, Norway. We have diverse backgrounds and expertise in biosciences and clinical medicine.
Our main projects involve optimising genome editing, along with personalised use of targeted therapies in rare diseases. We’re interested in rare and undiagnosed immunological diseases.
See our latest studies and research highlights in genome editing and novel genetic etiologies of immunological diseases in chronological order.
We have a new publication in the Journal of Allergy and Clinical Immunology
The paper is titled “SNIPSNP: Precision design of CRISPR/Cas9 knock-in reagents for variant correction and disease modeling”.
Henriette has successfully defended her Master thesis. Congratulations!
We are proud to be a part of the new Centre of Excellence: The Precision Immunotherapy Alliance (PRIMA).